title: [Pathogenesis of intestinal dysbacteriosis].
abstract: OBJECTIVE
  Study mechanism of the development of intestine dysbiosis on the experimental model of mice from the position of reinforcement of translocation of opportunistic Gram negative enterobacteria (OGNE) from the intestine lumen into the system blood flow and the possibility of its correction by lactoglobulin preparations.
  
  
  METHODS
  Experimental medicinal dysbacteriosis of the intestine was reproduced in mice by using gentamycin. Changes of immunologic parameters in the animals during translocation of Gram negative enterobacteria and their LPS from the intestine lumen into system blood flow were studied.
  
  
  RESULTS
  During intestine dysbioses a pronounced inflammatory reaction was shown to develop at a local level with the increase of the amount of proinflammatory cytokines with the sequence IL-1beta - IFNgamma- IL-6 and reinforcement of formation of anti-endotoxin antibodies. Changes in the parameters of allergization of macroorganism under the influence of LPS occurred synchronously with the increase of amount of (OGNE) including escherichia with altered lactase activity in the background of its translocation into extrinsic biotopes. In decompensated variant of dysbiosis a pronounced activation of immune reactive spleen cells was noted. Immunobiologic preparations (lactoglobulin and low molecular peptides of immune colostrum) administered to the animals in parallel with the antibiotic caused deintoxication and desensitizing effect and reduced the side effect of its action.
  
  
  CONCLUSIONS
  A scheme of development of dysbiotic disorders in the intestine from the position of reinforcement of translocation of (OGNE) from the intestine lumen into the system blood flow is proposed and mechanisms of positive effect of lactoglobulin preparations and low molecular peptides of immune colostrum that are perspective for the correction of this state are explained.
authors: A V
authors: AV
authors: Aleshukina
mesh_terms: D000818:Animals; D018988:Bacterial Translocation / Q000187:drug effects / Q000276:immunology; D003126:Colostrum / Q000737:chemistry / Q000276:immunology; D004755:Enterobacteriaceae / Q000187:drug effects / Q000502:physiology*; D005839:Gentamicins; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced / Q000276:immunology / Q000382:microbiology* / Q000517:prevention & control; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D053583:Interleukin-1beta / Q000096:biosynthesis / Q000276:immunology; D015850:Interleukin-6 / Q000096:biosynthesis / Q000276:immunology; D007422:Intestines / Q000187:drug effects / Q000276:immunology / Q000382:microbiology*; D007782:Lactoglobulins / Q000008:administration & dosage / Q000627:therapeutic use; D008070:Lipopolysaccharides / Q000276:immunology; D051379:Mice; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use; D013154:Spleen / Q000187:drug effects / Q000276:immunology
chemical_list: D005839:Gentamicins; D053583:Interleukin-1beta; D015850:Interleukin-6; D007782:Lactoglobulins; D008070:Lipopolysaccharides; D010455:Peptides; D007371:Interferon-gamma